title: Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination.
abstract: This study assessed the subjective and cardiovascular effects of relevant doses of cocaine administration during steady-state treatment of the combination of amantadine and baclofen compared to placebo. Participants included 8 healthy, male, cocaine-dependent, non-treatment-seeking individuals (age=36.6+/-5.9; 75% African American, 25% Caucasian; using cocaine for an average of 15.3+/-6.5 years). Data were collected prior to and following double-blind intravenous administration of 0 mg, 20 mg, and 40 mg of cocaine. Data were collected at baseline, following 5 days of treatment with placebo, and again following 5 days of treatment with a combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d. counterbalanced for order of medication and placebo in a cross-over design. Results showed no significant alterations to cardiovascular variables (heart rate, systolic and diastolic blood pressure) from treatment using combination medication or placebo in the presence of cocaine. Self-rated "desire" for cocaine was significantly lower during cocaine administrations while participants were receiving treatment with amantadine-baclofen compared to infusions while taking placebo medication, although there was no difference in the intensity of cocaine-induced euphoria, or reduction in the likelihood to use cocaine if given access. Study findings support the safety of the amantadine-baclofen combination treatment for cocaine dependence.
authors: UCLA Department of Family Medicine, 10880 Wilshire Blvd. Suite 1800, Los Angeles, CA 90024, USA. erf@ucla.edu
authors: Erin
authors: E
authors: Rotheram-Fuller
authors: Richard
authors: R
authors: De La Garza
authors: James J
authors: JJ
authors: Mahoney
authors: Steve
authors: S
authors: Shoptaw
authors: Thomas F
authors: TF
authors: Newton
mesh_terms: D000328:Adult; D000547:Amantadine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001418:Baclofen / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D019970:Cocaine-Related Disorders / Q000188:drug therapy*; D018592:Cross-Over Studies; D015259:Dopamine Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D015259:Dopamine Agents; D004338:Drug Combinations; D009125:Muscle Relaxants, Central; D000547:Amantadine; D001418:Baclofen